Studies 437 and 438Resistance Surveillance Results

• 10 patients with substitutions at conserved sites

  • 6 in placebo
  • 4 in ADV
    • 2 ADV 10 mg, 2 ADV 30 mg
    • S467A, H481L, V562A, H582Q
    • All had ~4 log10 copies/mL HBV DNA reductions at week 48 and no rebound viremia

• All susceptible to adefovir in vitro

• No adefovir-associated resistance mutations identified up to 48 weeks

Previous slide

Next slide

Back to first slide

View graphic version